
CELMoDs vs T-Cell-Redirecting Therapies at First Relapse in Relapsed/Refractory Multiple Myeloma
In the first round of the Hot Topics Debate, Team Catalyst and Team Compass discuss whether disease biology or patient context should carry greater weight when selecting treatment at first relapse in relapsed/refractory multiple myeloma.
Episodes in this series

In the first round of the Hot Topics Debate, Team Catalyst and Team Compass discuss whether disease biology or patient context should carry greater weight when selecting treatment at first relapse in relapsed/refractory multiple myeloma. Team Catalyst emphasizes disease biology, including high-risk cytogenetics, multiple genetic abnormalities, rapid relapse, disease tempo, and prior treatment exposure, to identify patients who may benefit from early T-cell-redirecting therapy. CELMoD-based regimens are discussed as potential options for patients with a slower relapse pattern or as a bridge to subsequent T-cell-redirecting therapy. Team Compass emphasizes patient-specific considerations, including comorbidities, frailty, treatment preferences, caregiver support, access to specialized centers, and the practical burden of travel and treatment. Faculty highlights the convenience of therapies that can be administered closer to home compared with approaches requiring specialized care and monitoring. The discussion underscores the importance of integrating disease biology, patient circumstances, treatment tolerability, and access when individualizing treatment decisions at first relapse.
Related to this article








